aMoon Life Science Fund Closes on $660 Million

March 6, 2019

Israeli healthcare-focused VC fund aMoon Partners has finalized $660 million in investor commitments for it second fund (aMoon II), making it the largest single fund in Israel. The fund, run by Israeli billionaire Marius Nacht, was launched in April of 2018.

The fund invests in mid to late stage life science companies focused on digital health, medical device and biopharmaceutical companies. aMoon I focuses on early-stage life science-based companies and has invested in 19 companies.

The fund released a statement on Wednesday. “We plan to leverage Israel’s ecosystem of breakthrough science and disruptive tech innovation to accelerate cure and reshape global healthcare.” said Dr. Yair Schindel, co-founder and managing partner of aMoon. “This raise is a vote of confidence for the Israeli healthtech ecosystem that extends beyond Israel’s borders, to include the sizable community of Israeli entrepreneurs and researchers in global hubs, such as Silicon Valley and Boston.”

The statement also noted that Israel has highly detailed electronic medical records for 98 percent of the population dating back 20 years, making it among the most valuable datasets in the world.

“The convergence of medicine and technology is generating a wave of innovation capable of redefining medical care – beyond our imagination. This presents a unique opportunity both for impacting human life and for the investor community.” said aMoon co-founder Marius Nacht.

CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.